Literature DB >> 10844404

Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group.

.   

Abstract

A pilot study was performed to compare the thromboprophylactic effect of danaparoid, enoxaparin and dalteparin in patients with hip fracture. The study was a prospective, randomised assessor-blind, four-centre trial. Prophylaxis was given for 9-11 days, whereafter bilateral phlebography was performed. A total of 197 patients were randomised. There were no statistically significant differences in the frequency of deep vein thrombosis, in blood loss or bleeding complications between the three prophylaxis groups. In conclusion, this moderately sized study revealed no statistically significant difference in efficacy or safety between danaparoid, enoxaparin and dalteparin in patients undergoing hip fracture surgery. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10844404     DOI: 10.1159/000022518

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  5 in total

Review 1.  Venous thromboembolic prophylaxis for hip fractures.

Authors:  D Marsland; S C Mears; S L Kates
Journal:  Osteoporos Int       Date:  2010-11-06       Impact factor: 4.507

Review 2.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Dalteparin versus Enoxaparin for the prevention of venous thromboembolic events in trauma patients.

Authors:  O T Okoye; R Gelbard; K Inaba; M Esparza; H Belzberg; P Talving; P G Teixeira; L S Chan; D Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2013-09-26       Impact factor: 3.693

4.  The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture.

Authors:  Ethan A Halm; Jason J Wang; Kenneth Boockvar; Joan Penrod; Stacey B Silberzweig; Jay Magaziner; Kenneth J Koval; Albert L Siu
Journal:  J Orthop Trauma       Date:  2004-07       Impact factor: 2.512

5.  Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines.

Authors:  Paolo Prandoni
Journal:  Thromb J       Date:  2008-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.